Abstract
Estrogens have been found to improve memory and reduce risk of dementia, although conflicting results such as failure of estrogen replacement therapy for treatment of Alzheimer's disease (AD) also has been reported. Only recently, our published human brain studies showed a depletion of brain estrogen in women with AD, while other studies have demonstrated cognitive impairment believed to be caused by inhibition of endogenous estrogen synthesis in females. To investigate whether the shortage of brain estrogen alters the sensitivity of response to estrogen replacement therapy, we have used genetic and surgical animal models to examine the response of estrogen treatment in AD neuropathology. Our studies have shown that early treatment with 17β-estradiol (E2) or genistein could reduce brain amyloid levels by increasing Aβ clearance in both APP23 mice with genetic deficiency of aromatase (APP/Ar+/−), in which the brains contain nondetectable levels of estrogen, and in APP23 mice with an ovariectomy (APP/OVX), in which the brains still contain certain levels of estrogen. However, only APP/Ar+/− mice showed a great reduction in brain amyloid plaque formation after E2 or genistein treatment along with downregulation of β-secretase (BACE1) mRNA and protein expression. Our results suggest that early and long-term usage of E2 and/or genistein may prevent AD pathologies in a dependent manner on endogenous brain estrogen levels in aged females.







Similar content being viewed by others
References
Schäfer S, Wirths O, Multhaup G, Bayer TA (2007) Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease. J Neural Transm 114:387–394
Carroll JC, Rosario ER, Kreimer S, Villamagna A, Gentzschein E, Stanczyk FZ, Pike CJ (2010) Sex differences in β-amyloid accumulation in 3xTg-AD mice: role of neonatal sex steroid hormone exposure. Brain Res 17(1366):233–245
Ryan J, Carrière I, Scali J, Ritchie K, Ancelin M-L (2009) Life-time estrogen exposure and cognitive functioning in later life. Psychoneuroendocrinol 34(2):287–298
Heys M, Jiang C, Cheng KK, Zhang W, Au Yeung SL, Lam TH, Leung GM, Schooling CM (2011) Life long endogenous estrogen exposure and later adulthood cognitive function in a population of naturally postmenopausal women from Southern China: the Guangzhou Biobank Cohort Study. Psychoneuroendocrinology 36(6):864–873
Tralongo R, Mari AD (2005) Cognitive impairment, aromatase inhibitors, and age. J Clin Oncol 23(18):4243
Wroolie TE, Kenna HA, Williams KE, Powers BN, Holcomb M, Khaylis A, Rasgon NL (2011) Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17β-estradiol versus conjugated equine estrogens. Am J Geriatr Psychiatry 19(9):792–802
Valen-Sendstad A, Engedal K, Stray-Pedersen B, ADACT Study Group, Strobel C, Barnett L, Meyer N, Nurminemi M (2010) Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone. Am J Geriatr Psychiatry 18(1):11–20
Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291:2947–2958
Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E (2002) Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med 113:543–548
Taylor HS, Manson JE (2011) Update in hormone therapy use in menopause. J Clin Endocrinol Metab 96:255–264
Silverman DH, Geist CL, Kenna HA, Williams K, Wroolie T, Powers B, Brooks J, Rasgon NL (2011) Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. Psychoneuroendocrinology 36(4):502–513
Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440):735–741
Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402(6761):533–537
De Strooper B, Vassar R, Golde T (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6(2):99–107, Review
Yang L-B, Lindholm K, Yan R, Citron M, Xia W, Konishi Y, Yang XL, Beach T, Sue L, Wang P, Price D, Li R, Shen Y (2003) Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer's brains. Nat Med 9:3–4
Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51(6):783–786
Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59(9):1381–1389
Yue X, Lu M, Lancaster T, Cao P, Honda S-I, Harada N, Staufenbiel M, Zhong ZY, Shen Y, Li R (2005) Brain estrogen deficiency accelerates Aβ plaque formation in Alzheimer's animal model. Proc Natl Acad Sci 102(52):19198–19203
Ertekin-Taner N, Allen M, Fadale D, Scanlin L, Younkin L, Petersen RC, Graff-Radford N, Younkin SG (2004) Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum Mutat 23:334–342
Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40(6):1087–1093
Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Aβ by neprilysin. Science 292:1550–1552
Xiao ZM, Sun L, Liu YM, Zhang JJ, Huang J (2009) Estrogen regulation of the neprilysin gene through a hormone-responsive element. J Mol Neurosci 39(1–2):22–26
Huang J, Guan H, Booze RM, Eckman CB, Hersh LB (2004) Estrogen regulates neprilysin activity in rat brain. Neurosci Lett 367(1):85–87
Yang HQ, Sun ZK, Jiang QH, Shang Q, Xu J (2009) Effect of estrogen-depletion and 17beta-estradiol replacement therapy upon rat hippocampus beta-amyloid generation. Zhonghua Yi Xue Za Zhi 89:2658–2661
Yaffe K, Sawaya G, Lieberburg I, Grady D (1998) Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279:688–695
Gibbs RB (1994) Estrogen and nerve growth factor-related systems in brain. Effects on basal forebrain cholinergic neurons and implications for learning and memory processes and aging. Ann N Y Acad Sci 743:165–196
Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA, MIRAGE Study Group (2005) Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry 76:103–105
Whitmer RA, Quesenberry CP, Zhou J, Yaffe K (2011) Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol 69:163–169
Wang CN, Chi CW, Lin YL, Chen CF, Shiao YJ (2001) The neuroprotective effects of phytoestrogenss on amyloid beta protein-induced toxicity are mediated by abrogating the activation of caspase cascade in rat cortical neurons. J Biol Chem 276:5287–5295
Zhao L, Mao Z, Brinton RD (2009) A select combination of clinically relevant phytoestrogens enhances estrogen receptor beta-binding selectivity and neuroprotective activities in vitro and in vivo. Endocrinology 150(2):770–783
Seidlova-Wuttke D, Hesse O, Jarry H, Christoffel V, Spengler B, Becker T, Wuttke W (2003) Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol 149(4):351–362
He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, Staufenbiel M, Li R, Shen Y (2007) Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 178(5):829–41
Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y (2004) Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci 101:3632–3637
McAllister C, Long J, Bowers A, Walker A, Cao P, Honda S-I, Harada N, Staufenbiel M, Shen Y, Li R (2010) Genetic targeting aromatase in male amyloid precursor protein (APP) transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment. J Neurosci 30:7326–7334
Song ES, Juliano MA, Juliano L, Hersh LB (2003) Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. J Biol Chem 278(50):49789–94
Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273(49):32730–32738
Li C, Hersh LB (1995) Neprilysin: assay methods, purification, and characterization. Methods Enzymol 48:253–263
Ait-Ghezala G, Mathura VS, Laporte V, Quadros A, Paris D, Patel N, Volmar CH, Kolippakkam D, Crawford F, Mullan M (2005) Genomic regulation after CD40 stimulation in microglia: relevance to Alzheimer's disease. Brain Res Mol Brain Res 140(1–2):73–85
Haisenleder DJ, Schoenfelder AH, Marcinko ES, Geddis LM, Marshall JC (2011) Estimation of estradiol in mouse serum samples: evaluation of commercial estradiol immunoassays. Endocrinology 152(11):4443–4447
Stanczyk FZ, Cho MM, Endres DB, Morrison JL, Patel S, Paulson RJ (2003) Limitations of direct estradiol and testosterone immunoassay kits. Steroids 68(14):1173–1178
Ter Horst JP, de Kloet ER, Schächinger H, Oitzl MS (2012) Relevance of stress and female sex hormones for emotion and cognition. Cell Mol Neurobiol 32(5):725–735
Lin J, Kroenke CH, Epel E, Kenna HA, Wolkowitz OM, Blackburn E, Rasgon NL (2011) Greater endogenous estrogen exposure is associated with longer telomeres in postmenopausal women at risk for cognitive decline. Brain Res 1379:224–231
Phillips KA, Ribi K, Fisher R (2011) Do aromatase inhibitors have adverse effects on cognitive function? Breast Cancer Res 13:203
Sherwin BB (2003) Estrogen and cognitive functioning in women. Endocr Rev 24:133–151
Hojo Y, Murakami G, Mukai H, Higo S, Hatanaka Y, Ogiue-Ikeda M, Ishii H, Kimoto T, Kawato S (2008) Estrogen synthesis in the brain—role in synaptic plasticity and memory. Mol Cell Endocrinol 290(1–2):31–43
Butler HT, Warden DR, Hogervorst E, Ragoussis J, Smith AD, Lehmann DJ (2010) Association of the aromatase gene with Alzheimer's disease in women. Neurosci Lett 468(3):202–206
Kretz O, Fester L, Wehrenberg U, Zhou L, Brauckmann S, Zhao S, Prange-Kiel J, Naumann T, Jarry H, Frotscher M, Rune GM (2004) Hippocampal synapses depend on hippocampal estrogen synthesis. J Neurosci 24(26):5913–5921
Froyen EB, Steinberg FM (2011) Soy isoflavones increase quinone reductase in hepa-1c1c7 cells via estrogen receptor beta and nuclear factor erythroid 2-related factor 2 binding to the antioxidant response element. J Nutr Biochem 22(9):843–848
Trivella DB, Bleicher L, Palmieri Lde C, Wiggers HJ, Montanari CA, Kelly JW, Lima LM, Foguel D, Polikarpov I (2010) Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding. J Struct Biol 170(3):522–531
Pan M, Han H, Zhong C, Geng Q (2012) Effects of genistein and daidzein on hippocampus neuronal cell proliferation and BDNF expression in H19-7 neural cell line. J Nutr Health Aging 16(4):389–394
Sohrabji F, Miranda RC, Toran-Allerand CD (1995) Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proc Natl Acad Sci USA 92(24):11110–11114
Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15:331–337
Acknowledgments
This work was supported by grants from the Alzheimer's Association IIRG-07-59510, American Health Assistance Foundation Grant G2006-118, NIH R01AG032441, and NIH R01AG025888. We thank Mr. Alex Bishop for editing and proofreading the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, R., He, P., Cui, J. et al. Brain Endogenous Estrogen Levels Determine Responses to Estrogen Replacement Therapy via Regulation of BACE1 and NEP in Female Alzheimer’s Transgenic Mice. Mol Neurobiol 47, 857–867 (2013). https://doi.org/10.1007/s12035-012-8377-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-012-8377-3